@article{10.37349/en.2026.1006121,
abstract = {Cerebral amyloid angiopathy (CAA), characterized by amyloid β deposition in cerebral vasculature, is increasingly recognized as a major contributor to both cognitive decline and lobar intracerebral hemorrhage (ICH) in older adults and often coexists with Alzheimer's disease (AD). Understanding CAA is a crucial step for improving health outcomes and the development of effective therapies. However, significant gaps remain in our understanding of CAA's pathophysiology, diagnostic approaches, biomarker development, and clinical management. A comprehensive review is therefore essential to synthesize existing knowledge and highlight key directions for future research. This review goes beyond prior summaries by critically synthesizing recent evidence on diagnostic innovations—including the Boston criteria v2.0 and emerging plasma biomarkers—and addressing pressing clinical dilemmas such as anticoagulation management in patients with coexisting atrial fibrillation and CAA. It also highlights ongoing research into multimodal diagnostic frameworks and precision treatment strategies aimed at bridging current diagnostic and therapeutic gaps. Together, these updates underscore how advancing biomarker validation, individualized risk stratification, and amyloid-targeted approaches may shape future CAA management and prevention.},
author = {Willsey, Trinity and Faselis, Charles and Ahmed, Ali and Sin, Mo-Kyung},
doi = {10.37349/en.2026.1006121},
journal = {Exploration of Neuroscience},
elocation-id = {1006121},
title = {Cerebral amyloid angiopathy: updates on pathophysiology, diagnosis, and management},
url = {https://www.explorationpub.com/Journals/en/Article/1006121},
volume = {5},
year = {2026}
}